Nabriva Therapeutics AG (NASDAQ:NBRV) had its target price lifted by research analysts at HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 226.80% from the company’s current price.
Other analysts have also recently issued reports about the stock. SunTrust Banks, Inc. boosted their price objective on shares of Nabriva Therapeutics AG from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, September 18th. Leerink Swann restated an “outperform” rating and issued a $22.00 price objective (up from $20.00) on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Thursday, August 10th. Finally, ValuEngine cut shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Nabriva Therapeutics AG presently has an average rating of “Buy” and a consensus price target of $19.03.
Shares of Nabriva Therapeutics AG (NASDAQ NBRV) opened at 6.12 on Wednesday. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $14.10. The company’s 50-day moving average is $7.56 and its 200-day moving average is $9.32. The firm’s market capitalization is $164.25 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. On average, equities analysts forecast that Nabriva Therapeutics AG will post ($2.29) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) PT Raised to $20.00” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/11/01/nabriva-therapeutics-ag-nbrv-pt-raised-to-20-00.html.
In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 17,790 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $10.50, for a total value of $186,795.00. Following the sale, the insider now owns 2,373,387 shares of the company’s stock, valued at approximately $24,920,563.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Vivo Capital Viii, Llc purchased 52,631 shares of the stock in a transaction on Monday, September 18th. The stock was acquired at an average cost of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. In the last three months, insiders acquired 57,219 shares of company stock worth $535,919 and sold 74,840 shares worth $714,161. Insiders own 2.75% of the company’s stock.
A number of institutional investors have recently made changes to their positions in NBRV. Almanack Investment Partners LLC. increased its holdings in Nabriva Therapeutics AG by 482.2% in the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after buying an additional 751,366 shares during the period. Nationwide Fund Advisors grew its holdings in shares of Nabriva Therapeutics AG by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after purchasing an additional 7,924 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares during the last quarter. 50.24% of the stock is currently owned by hedge funds and other institutional investors.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.